A new trading day began on Tuesday, with Syros Pharmaceuticals Inc. (NASDAQ: SYRS) stock price up 19.91% from the previous day of trading, before settling in for the closing price of $2.11. SYRS’s price has ranged from $1.43 to $8.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 128.79% over the past five years. Meanwhile, its annual earnings per share averaged 64.31%. With a float of $19.76 million, this company’s outstanding shares have now reached $26.45 million.
Let’s look at the performance matrix of the company that is accounted for 68 employees. In terms of profitability, gross margin is 62.39%, operating margin of -2892.43%, and the pretax margin is -3171.7%.
Syros Pharmaceuticals Inc. (SYRS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Syros Pharmaceuticals Inc. is 26.31%, while institutional ownership is 56.07%. The most recent insider transaction that took place on Sep 11 ’24, was worth 85,420. In this transaction President & CEO of this company bought 50,000 shares at a rate of $1.71, taking the stock ownership to the 122,504 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Financial Officer bought 45,344 for $1.68, making the entire transaction worth $76,006. This insider now owns 124,552 shares in total.
Syros Pharmaceuticals Inc. (SYRS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 64.31% per share during the next fiscal year.
Syros Pharmaceuticals Inc. (NASDAQ: SYRS) Trading Performance Indicators
Here are Syros Pharmaceuticals Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.30, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.71 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc. (SYRS)
Syros Pharmaceuticals Inc. (NASDAQ: SYRS) saw its 5-day average volume 0.61 million, a positive change from its year-to-date volume of 0.24 million. As of the previous 9 days, the stock’s Stochastic %D was 42.42%. Additionally, its Average True Range was 0.24.
During the past 100 days, Syros Pharmaceuticals Inc.’s (SYRS) raw stochastic average was set at 20.01%, which indicates a significant decrease from 74.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.06% in the past 14 days, which was lower than the 174.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.88, while its 200-day Moving Average is $4.80. Nevertheless, the first resistance level for the watch stands at $2.86 in the near term. At $3.18, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.60. If the price goes on to break the first support level at $2.12, it is likely to go to the next support level at $1.70. The third support level lies at $1.38 if the price breaches the second support level.
Syros Pharmaceuticals Inc. (NASDAQ: SYRS) Key Stats
With a market capitalization of 67.83 million, the company has a total of 26,810K Shares Outstanding. Currently, annual sales are 9,940 K while annual income is -164,570 K. The company’s previous quarter sales were 0 K while its latest quarter income was -3,710 K.
